T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
Valmont Industries
VMI
$9.5B
| $27.4M | ﹤0.01% |
94,256
-2,017
| -2% | -$583K |
|
852
Bloomin' Brands
BLMN
$924M
| $27.4M | ﹤0.01% |
1,019,626
+25,870
| +3% | +$648K |
|
853
Acadia Healthcare
ACHC
$2.82B
| $27.3M | ﹤0.01% |
343,017
-6,953
| -2% | -$502K |
|
|
WBA
854
DELISTED
Walgreens Boots Alliance
WBA
| $27.2M | ﹤0.01% |
955,605
-8,835
| -0.9% | -$288K |
|
855
ICU Medical
ICUI
$4.58B
| $27.2M | ﹤0.01% |
152,516
-14,596
| -9% | -$2.68M |
|
856
Iron Mountain
IRM
$37.7B
| $27M | ﹤0.01% |
475,549
+1,678
| +0.4% | +$91.9K |
|
|
ARCE
857
DELISTED
Arco Platform Limited Class A Common Shares
ARCE
| $26.7M | ﹤0.01% |
2,203,118
-16,400
| -0.7% | -$194K |
|
858
Monte Rosa Therapeutics
GLUE
$1.35B
| $26.7M | ﹤0.01% |
3,896,498
+203,004
| +5% | +$1.31M |
|
859
Invitation Homes
INVH
$18B
| $26.6M | ﹤0.01% |
774,542
+2,216
| +0.3% | +$74K |
|
860
Allogene Therapeutics
ALLO
$683M
| $26.5M | ﹤0.01% |
5,331,400
-998,904
| -16% | -$5.4M |
|
861
Brown & Brown
BRO
$24B
| $26.3M | ﹤0.01% |
382,587
-3,318,277
| -90% | -$211M |
|
862
Grupo Aeroportuario del Sureste
ASR
$8.01B
| $26.3M | ﹤0.01% |
94,601
-660
| -0.7% | -$190K |
|
863
Tenaya Therapeutics
TNYA
$164M
| $26.2M | ﹤0.01% |
4,469,641
+82,858
| +2% | +$482K |
|
864
Graco
GGG
$13.3B
| $26.1M | ﹤0.01% |
302,450
-41,461
| -12% | -$3.22M |
|
|
PPL
865
PPL Corp
PPL
$26.8B
| $26.1M | ﹤0.01% |
986,764
-619
| -0.1% | -$17.1K |
|
866
Morningstar
MORN
$7.76B
| $26M | ﹤0.01% |
132,583
+101,381
| +325% | +$20.1M |
|
867
Pebblebrook Hotel Trust
PEB
$2.05B
| $26M | ﹤0.01% |
1,862,784
-980,830
| -34% | -$13.7M |
|
868
Lyell Immunopharma
LYEL
$337M
| $26M | ﹤0.01% |
408,055
+209,688
| +106% | +$11.6M |
|
869
Iovance Biotherapeutics
IOVA
$2.95B
| $25.8M | ﹤0.01% |
3,663,373
-92,495
| -2% | -$662K |
|
870
Evolent Health
EVH
$527M
| $25.8M | ﹤0.01% |
850,261
+6,317
| +0.7% | +$204K |
|
871
Crinetics Pharmaceuticals
CRNX
$8.96B
| $25.8M | ﹤0.01% |
1,428,910
+1,387,127
| +3,320% | +$27.7M |
|
|
SPNS
872
DELISTED
Sapiens International
SPNS
| $25.7M | ﹤0.01% |
965,712
-43,539
| -4% | -$1.03M |
|
873
Pultegroup
PHM
$24.9B
| $25.6M | ﹤0.01% |
329,220
-26
| -0% | -$1.76K |
|
874
Allegion
ALLE
$14.2B
| $25.3M | ﹤0.01% |
211,136
+20,528
| +11% | +$2.24M |
|
|
FTCH
875
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $25.3M | ﹤0.01% |
4,187,178
-2,685,950
| -39% | -$12.9M |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.